BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu W, Ji Z, Wu B, Huang S, Chen Q, Chen X, Wei Y, Jiang J. Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. FEBS Lett 2021. [PMID: 34328657 DOI: 10.1002/1873-3468.14169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Song K, Ma J, Gao Y, Qu Y, Ren C, Yan P, Zheng B, Yue B. Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway. Adv Med Sci 2022;67:187-95. [PMID: 35398779 DOI: 10.1016/j.advms.2022.03.001] [Reference Citation Analysis]
2 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liao C, Wang Q, An J, Chen J, Li X, Long Q, Xiao L, Guan X, Liu J. CD44 Glycosylation as a Therapeutic Target in Oncology. Front Oncol 2022;12:883831. [DOI: 10.3389/fonc.2022.883831] [Reference Citation Analysis]
4 Lim J, Sari-Ak D, Bagga T. Siglecs as Therapeutic Targets in Cancer. Biology (Basel) 2021;10:1178. [PMID: 34827170 DOI: 10.3390/biology10111178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Wen R, Zhao H, Zhang D, Chiu CL, Brooks JD. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer. Carbohydrate Research 2022. [DOI: 10.1016/j.carres.2022.108598] [Reference Citation Analysis]